All In Biotech

BLA 020744 · Chiesi USA INC

Curosurf

Poractant Alfa · Intratracheal · Surfactant

NovelOrphan

Last checked: Nov 20, 2026Latest source record: May 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Nov 18, 1999

Approved uses

2

Original approval plus efficacy supplements

Registered trials

38

7 Phase 3, 4 recruiting

FAERS reports

737

685 serious, 222 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 10, 2025.

CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. CUROSURF is a surfactant indicated for the rescue treatment, including the reduction of mortality and pneumothoraces, of Respiratory Distress Syndrome (RDS) in premature infants. ( 1 )

Mechanism: Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis). CUROSURF compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 1, 2002 Supplement 4 · Efficacy Letter
  • Nov 18, 1999 Original approval · Type 1 - New Molecular Entity LabelReviewLetter
1 products under this application
  • CUROSURF · PORACTANT ALFA 80MG/ML · SUSPENSION, INTRATRACHEAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Poractant Alfa" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neonatal hypoxia121
  • off label use84
  • pulmonary haemorrhage78
  • bradycardia neonatal51
  • ill-defined disorder50
  • drug ineffective46
  • product complaint40
  • endotracheal intubation complication39
  • pneumothorax37
  • infantile apnoea30
  • neonatal respiratory failure28
  • pulmonary haemorrhage neonatal28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
20054
200616
200716
200812
20098
20109
20114
201213
201316
201411
201515
201618
201731
2018145
201968
2020109
202141
202254
202342
202456
202516
202628

Recalls

1 FDA enforcement reports for this application.

  • Mar 17, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 110 on PubMed

Sponsor: Chiesi USA INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.